The purpose of this study was to evaluate the impact of CERA treatment by using methoxy polyethylene glycol-epoetin (MPG-EPO) beta on selected CVD risk biomarkers, especially of inflammation and endothelial dysfunction, and left ventricle structure and function, in nondialyzed CKD patients. Here, EPO is linked to endothelial dysfunction.